Kodiak Sciences Inc. (KOD )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol KOD
- Company Kodiak Sciences Inc.
- Price $24.12
- Changes Percentage -1.79
- Change -0.44
- Day Low $23.81
- Day High $25.37
- Year High $26.21
- Year Low $1.92
- Market Cap $1,276,676,376
- Price Avg 50 EMA (D) $18.69
- Price Avg 200 EMA (D) $8.95
- Exchange NASDAQ
- Volume 467,922
- Average Volume 929,492
- Open $24.59
- Previous Close $24.56
- EPS -4.12
- PE -5.85
- Earnings Announcement 2026-03-26 04:00:00
- Shares Outstanding $52,930,198
Company brief: KODIAK SCIENCES INC. (KOD )
- Healthcare
- Biotechnology
- Dr. Victor Perlroth M.D.
- https://kodiak.com
- US
- N/A
- 10-04-2018
- US50015M1099
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.